Is Cetrorelix approved as a medicine, and where?

It is an approved prescription medicine, but where it is approved matters: FDA (United States; controlled ovarian stimulation). It should only be used under medical supervision.

What is Cetrorelix studied for?

Cetrorelix is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.

Does Cetrorelix have human clinical trials?

Yes. Cetrorelix has been studied in human clinical trials and is an approved medicine in at least some regions.

Index by category›

Reproductive & Hormonal

Cetrorelix

Cetrotide; cetrorelix acetate

1 min read · Updated July 27, 2026 · 3 references

Curated by PeptideInfo Wikilast reviewed July 27, 2026how we verify

Explored forApproved peptide medicines — verification pilot

In brief · TL;DR

Approved medicine· US

An approved GnRH antagonist used during controlled ovarian stimulation to prevent a premature LH surge and ovulation.

Evidence: Regulator-approved drug with human trial evidence.

Approved in: FDA (United States; controlled ovarian stimulation)

An approved GnRH antagonist used during controlled ovarian stimulation to prevent a premature LH surge and ovulation.
It competitively blocks pituitary GnRH receptors; suppression is rapid and reversible, without the initial agonist flare.
Hypersensitivity, including rare severe reactions, can occur. Treatment belongs in a monitored fertility protocol because ovarian response and OHSS risk determine the wider regimen.

↓ Read the full referenced entry below

An approved GnRH antagonist used during controlled ovarian stimulation to prevent a premature LH surge and ovulation.

Contents4

Section 1 of 4Overview

Overview

An approved GnRH antagonist used during controlled ovarian stimulation to prevent a premature LH surge and ovulation.

Primary regulatory source

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

Section 2 of 4Identity and mechanism

Identity and mechanism

It competitively blocks pituitary GnRH receptors; suppression is rapid and reversible, without the initial agonist flare.

PubChem CID 25074887; C70H92ClN17O14; 1431.0 Da.

Section 3 of 4Regulatory label facts

Regulatory label facts

FDA (United States; controlled ovarian stimulation).

The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Cetrotide: 0.25 mg subcutaneously once daily from stimulation day 5 or 6 through the day of hCG administration, under specialist monitoring.

Section 4 of 4Safety boundary

Safety boundary

Hypersensitivity, including rare severe reactions, can occur. Treatment belongs in a monitored fertility protocol because ovarian response and OHSS risk determine the wider regimen.

This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.

References3

References

1.
Cetrorelix — Primary regulatory source source
2.
Cetrorelix — PubChem compound record source
3.
Cetrorelix — Human study source

Frequently asked questions4

Frequently asked questions

What is Cetrorelix?: An approved GnRH antagonist used during controlled ovarian stimulation to prevent a premature LH surge and ovulation.
Is Cetrorelix approved as a medicine, and where?: It is an approved prescription medicine, but where it is approved matters: FDA (United States; controlled ovarian stimulation). It should only be used under medical supervision.
What is Cetrorelix studied for?: Cetrorelix is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
Does Cetrorelix have human clinical trials?: Yes. Cetrorelix has been studied in human clinical trials and is an approved medicine in at least some regions.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Cetrorelix is an approved medicine within the stated approval scope (FDA (United States; controlled ovarian stimulation)) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.

Overview

Identity and mechanism

Regulatory label facts

Safety boundary

References

Frequently asked questions

Related in Reproductive & Hormonal